Modi, Obama write first joint editorial

Washington, Jun 24: Twitter has once again flagged a tweet from US President Donald Trump which promoted violence by saying if protesters tried to set up an "autonomous zone" in Washington, DC they would be met with "serious force".

This is the fourth time Twitter has red flagged Trump's tweet for glorifying violence or violating its policies.

Trump has been critical of the "autonomous zone" in Seattle, an area occupied by protestors for much of this month.

"We've placed a public interest notice on this Tweet for violating our policy against abusive behaviour, specifically, the presence of a threat of harm against an identifiable group," Twitter's safety team tweeted late Tuesday.

Trump had tweeted: "There will never be an ‘Autonomous Zone' in Washington, D.C., as long as I'm your President. If they try they will be met with serious force!"

Twitter earlier labeled a video tweeted by him which mocked CNN as manipulated media.

According to Twitter, "this Tweet has been labeled per our synthetic and manipulated media policy to give people more context".

In May, Twitter labeled two Trump tweets that made false claims about mail-in ballots in California.

Twitter later labeled another Trump tweet glorifying violence in which he said, "when the looting starts, the shooting starts."

Facebook also removed a Trump campaign ad featuring a symbol used by Nazis for political dissenters, saying the ad violated its policies.

Beijing, Jun 11: Floods and mudslides in south China have uprooted hundreds of thousands of people and left dozens dead or missing, state media reported Thursday.

The bad weather has wreaked havoc on popular tourist areas that had already been battered by months of travel restrictions during the coronavirus outbreak.

Torrential downpours unleashed floods and mudslides that caused nearly 230,000 people to be relocated and destroyed more than 1,300 houses, official state news agency Xinhua reported, citing the Ministry of Emergency Management.

In southern Guangxi Zhuang Autonomous Region, six people were reported dead and one missing, Xinhua said.

Streets were waterlogged in popular tourist destination Yangshuo, forcing residents and visitors to evacuate on bamboo rafts.

The local government said more than 1,000 hotels had been flooded and more than 30 tourist sites damaged.

One owner of a family-run hotel told Xinhua that the guest rooms were submerged in one metre (three feet) of rainwater.

The extreme weather has dealt a hefty blow to the region's tourism sector, which is still reeling from the COVID-19 epidemic.

The emergency management ministry said there were direct economic losses of over 4 billion yuan (more than $550 million) from the flooding, Xinhua reported.

In Hunan Province, at least 13 people were killed in rain-triggered disasters, and another eight people are missing or killed in southwestern Guizhou province, according to the local emergency response departments, Xinhua said.

The heavy downpours began at the beginning of June and have led to "dangerously high water levels" in 110 rivers, Xinhua reported.

Further rainstorms are expected in the next few days across the south.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.